ZTI BIOSCIENCES specializes in the development of radiopharmaceuticals for cancer therapeutics based on the Nano-tech platform (TERACARRIER™), distinguished as the world's first and only technology. We are a drug delivery platform company that can deliver not only radiopharmaceuticals for treating diseases but also work with antibody-drug conjugates (ADCs) and immune-checkpoint inhibitors to target tumors with potentially higher efficacy, lower doses, and lower toxicity. [Pipeline] We are placing our focus on ZTI-201A, a formulation conjugated with Anti-HER2 for Ultra Low HER2 Expressing Cancer. Leveraging our proprietary technology, TERACARRIER™, ZTI-201A addresses the treatment challenges associated with Ultra Low HER2 Expressing Cancer, a condition with significantly fewer licensed drugs available. [Business Model] BM1) Validating TERACARRIER™ through IND BM2) Licensing out pipelines and expanding them based on the TERACARRIER™ platform BM3) Launching CDMO based on TERACARRIER™